A combined recovery-focused research pathway requiring clinical and regulatory review.
This combination brings together two experimental peptide pathways commonly discussed in recovery settings. Combining them does not establish effectiveness, and robust human trial evidence for the combination is lacking.
Potential uses depend on the exact formulation, evidence and clinician assessment.
Mechanism is ingredient- and formulation-specific.
Both BPC-157 and TB-500 are named in SAHPRA public information on illegally marketed peptides. The combination is not available for routine online purchase.
Suitability, contraindications, interactions and monitoring should be reviewed where clinically relevant.
Viewing this page or booking an assessment does not guarantee a prescription. A clinician independently determines suitability and any medicine must move through the appropriate pharmacy or supply pathway.
Book a clinician-led assessment so suitability and the appropriate treatment pathway can be reviewed.
Book assessmentProduct formulation, pack and pricing information are based on the supplied clinic/pharmacy catalogue data. Availability should be confirmed before fulfilment.